Frazier Life Sciences Acquisition Corp. II (NASDAQ:FLSC – Get Free Report) was the target of a large growth in short interest in the month of October. As of October 15th, there was short interest totaling 17,259 shares. Approximately 0.2% of the shares of the company are sold short. Based on an average daily volume of 112,857 shares, the days-to-cover ratio is currently 0.2 days.
Frazier Life Sciences Acquisition Corp. II Stock Performance
NASDAQ:FLSC traded down $0.04 on Friday, reaching $10.17. The company’s stock had a trading volume of 3,763 shares, compared to its average volume of 141,373. Frazier Life Sciences Acquisition Corp. II has a 12-month low of $10.10 and a 12-month high of $10.63.
Insider Buying and Selling
In other news, CEO Albert Cha purchased 300,000 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The shares were bought at an average price of $10.00 per share, for a total transaction of $3,000,000.00. Following the completion of the transaction, the chief executive officer owned 300,000 shares in the company, valued at $3,000,000. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link.
Analysts Set New Price Targets
Separately, Wall Street Zen upgraded shares of Frazier Life Sciences Acquisition Corp. II to a “hold” rating in a research report on Saturday, October 24th.
View Our Latest Report on Frazier Life Sciences Acquisition Corp. II
About Frazier Life Sciences Acquisition Corp. II
Frazier Life Sciences Acquisition Corp. II is a special purpose acquisition company, or SPAC, focused on identifying and combining with a business in the life sciences sector. The company does not operate a conventional commercial business and was formed to pursue a merger, acquisition, or similar business combination.
Its target opportunities may include companies involved in biotechnology, pharmaceuticals, medical devices, diagnostics, or other healthcare-related technologies. The company’s objective is to provide a publicly traded platform for a private life sciences business through a business combination.
Frazier Life Sciences Acquisition Corp.
Further Reading
- Five stocks we like better than Frazier Life Sciences Acquisition Corp. II
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for Frazier Life Sciences Acquisition Corp. II Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Frazier Life Sciences Acquisition Corp. II and related companies with MarketBeat.com's FREE daily email newsletter.
